Akeso Showcases Groundbreaking IL-1RAP Antibody Research
Akeso, Inc. (HKEX: 9926.HK) has unveiled promising data from preclinical studies of a new monoclonal antibody known as AK135. This innovative treatment specifically targets the IL-1 receptor accessory protein (IL-1RAP) and effectively blocks multiple pro-inflammatory pathways. The recent findings were presented at a notable meeting of immunotherapy specialists.
Unveiling Promising Results for AK135
AK135 demonstrates a remarkable ability to inhibit critical inflammatory signaling processes, namely those triggered by IL-1, IL-33, and IL-36. These pathways are central to the generation of inflammatory signals that can lead to significant pain and health complications. The challenging nature of neuropathy, particularly when induced by chemotherapy, has spurred the development of this novel therapeutic option, which aims to provide relief for many patients affected by such conditions.
Key Findings from Preclinical Studies
The preclinical evaluation revealed that AK135 not only binds effectively to its target but also successfully interrupts inflammatory signaling cascades. The research involved robust methodologies, including ELISA and flow cytometry tests, confirming the affinity of AK135 for IL-1RAP is on par with or superior to existing therapies.
In vitro studies showcased AK135’s potency by demonstrating its efficiency in inhibiting IL-1, IL-33, and IL-36 pathways, along with reduced pro-inflammatory cytokine secretion from tumor cell models. There was noted efficacy in reducing cytokine levels that contribute to the inflammatory processes associated with chemotherapy-induced peripheral neuropathy (CIPN).
In Vivo Impact and Safety Profile
To further assess the therapeutic potential of AK135, comprehensive in vivo studies were conducted. In a specially designed mouse model simulating CIPN, continuous treatment with AK135 resulted in significantly improved pain thresholds. Encouragingly, the mice displayed normal body weights and exhibited no signs of toxicity throughout the treatment duration, underlining the favorable safety profile of AK135.
The Clinical Significance of CIPN
Chemotherapy-induced neuropathy remains a substantial concern in cancer treatment, impacting a considerable proportion of patients undergoing therapy. With around 50-90% experiencing this side effect, the need for effective interventions is pressing. The disruption of pain signaling mechanisms, as demonstrated by AK135 in these studies, offers potential pathways to alleviate this pervasive issue.
About the Groundbreaking Antibody AK135
AK135 is characterized as an antagonistic monoclonal antibody specifically engineered by Akeso to target IL-1RAP. This novel approach provides a dual function by combating the inflammatory pathways implicated in neuropathic pain. Its development is crucial as it enters clinical trial phases, bringing hope to those faced with chronic pain as a result of cancer therapy.
About Akeso
Established in 2012, Akeso (HKEX: 9926.HK) is recognized as a pioneering biopharmaceutical company dedicated to advancing innovative medical treatments. With a diverse pipeline exceeding 50 drug candidates, Akeso focuses on various diseases, including cancer and autoimmune disorders. The company’s advanced research and development framework integrates proprietary technologies to streamline the creation of biopharmaceuticals, ensuring that affordable treatments reach patients globally.
Frequently Asked Questions
What is AK135?
AK135 is a novel monoclonal antibody developed by Akeso that targets IL-1RAP to inhibit inflammatory signaling pathways associated with chemotherapy-induced neuropathy.
How does AK135 work?
It works by blocking the IL-1, IL-33, and IL-36 signaling pathways, which play a critical role in the development of pain in neuropathic conditions.
What were the results of the preclinical studies?
The studies demonstrated AK135's strong binding affinity, effective signaling pathway inhibition, and significant pain relief in applicable models, indicating a robust therapeutic potential.
Is AK135 safe for patients?
The studies indicated a good safety profile, with no significant toxicity and stable body weight observed among the treated subjects.
When will AK135 be available for patients?
AK135 is currently undergoing Phase I clinical trials, and further information will be released as it advances through testing and regulatory approvals.
